2020-07-09T14:28:33-05:00 2019-06-30 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 100172703 990 2018-07-01 133540234 THE AARON DIAMOND AIDS RESEARCH CENTER FOR the city of new york % KEVIN O'ROURKE AARO 2123046104 701 West 168th Street 11th Floor NEW YORK NY 10032 KEVIN O'ROURKE CFO 2123046104 2020-07-08 true WILLIAM EPSTEIN P01307171 2129498700 64.238.150.4 26505220201915000351 2020-07-09 P 45E03A01E385EA2FD4321D9DC7B70482997C2D58 F90492970AD88B7D13614175ECFF51901F1316F6 2018 2021-01-29 14:40:06Z X DR DAVID HO 701 West 168th Street 11th Floor NEW YORK NY 10032 19403552 false X WWW.ADARC.ORG X 1988 NY AIDS RESEARCH 10 9 59 2 6 10656034 8972211 56072 90589 7896351 2132212 0 0 18608457 11195012 0 0 0 0 7301549 7479429 0 0 0 8065704 6738091 15367253 14217520 3241204 -3022508 69338106 63817934 5597200 4342144 63740906 59475790 X AIDS RESEARCH (See also schedule O) false false 11066517 90589 THE AARON DIAMOND AIDS RESEARCH CENTER (ADARC) is the world's largest private hiv/aids research center. ADARC is committed to finding solutions to end the aids epidemic by conducting basic discovery research, and by developing novel therapies, vaccines and other prevention strategies. 11066517 true true false false false false false false false true true true false false false true true false false false true false false false false false false false false true false false false false false false false false false false false false false false false false false true 40 0 59 true false false false false false false false false false false false false X 10 9 false false false false false false false true true false false true true true true true true true true false CA CT DC FL IL MD MA NJ NY OH PA VA X KEVIN O'ROURKE 2123046104 701 WEST 168TH STREET 11TH FLOOR NEW YORK NY 10032 X DR DAVID D HO CHIEF EXECUTIVE OFFICER 35.0 0.0 X X 821284 0 104273 GERALD FRIEDLAND MD CHAIRMAN OF THE BOARD 1.0 0.0 X X 0 0 0 SAVIO TUNG TREASURER 1.0 0.0 X X 0 0 0 blayne cutler md phd DIRECTOR 1.0 0.0 X 0 0 0 MARTIN S HIRSCH MD DIRECTOR 1.0 0.0 X 0 0 0 MAY-KIN HO PHD DIRECTOR 1.0 0.0 X 0 0 0 TIMOTHY O'CONNOR PHD Director 1.0 0.0 X 0 0 0 DEMETRE DASKALAKIS MD DIRECTOR 1.0 0.0 X 0 0 0 DIANA VINOLY Director (Through 10/2018) 1.0 0.0 X 0 0 0 DAVID S PERLIN PHD DIRECTOR 1.0 0.0 X 0 0 0 WALTER WANG DIRECTOR (Through 10/2018) 1.0 0.0 X 0 0 0 Dafna Bar-Sagi PHD DIRECTOR 1.0 0.0 X 0 0 0 SUKI TERRADA PORTS SECRETARY 1.0 0.0 X 0 0 0 KEVIN O'ROURKE CHIEF FINANCIAL OFFICER 35.0 0.0 X 301143 0 81105 STEPHANIE SOZOMENU CHIEF OPERATING OFFICER 35.0 0.0 X 325202 0 65023 MORIYA TSUJI SCIENTIST 35.0 0.0 X 174024 0 50773 YAOXING HUANG SCIENTIST 35.0 0.0 X 213894 0 55857 MARTIN MARKOWITZ INVESTIGATOR SCIENTIST 35.0 0.0 X 247540 0 60952 VINCENT SAHI CORE FACILITIES MANAGER 35.0 0.0 X 137458 0 61275 XUELING WU SCIENTIST 35.0 0.0 X 139148 0 61319 2359693 0 540577 12 false true false CS BUILDING SERVICES 152 TOLEDO STREET FARMINGDALE NY 11735 BUILDING SERVICES 330000 ADVANCED TECHNOLOGY 20 CEDAR STREET SUITE 104 NEW ROCHELLE NY 10801 COMPUTER SUPPORT 195392 TULANE UNIVERSITY 800 East Commerce Rd Suite 203 COVINGTON LA 70433 RESEARCH SUPPORT 364198 Venable LLP 1270 Avenue of the Americas 24th Fl NEW YORK NY 10020 Attorney 212494 Lord Aeck Sargent 1175 Peachtree St NE suite 2400 ATALANTA GA 30361 Architect 455762 6 3765558 5206653 8972211 REVENUE FROM CLINICAL TRIALS 541380 90589 90589 90589 2272851 6 2272845 0 0 0 0 0 8067901 8208540 -140639 -140639 -140639 0 0 0 0 0 0 0 0 0 0 11195012 90589 6 2132206 0 0 0 0 1728033 1208641 519392 0 3374031 2359906 1014125 676690 448776 227914 1393390 924087 469303 307285 203789 103496 0 7285 7285 93000 93000 0 0 160945 160945 763499 473602 289897 0 66814 58984 7830 0 0 1083278 932487 150791 164128 137858 26270 0 0 0 0 150599 118973 31626 239347 206635 32712 UTILITIES 312627 310365 2262 LAB SUPPLIES 641943 641943 ANIMAL FEES 509157 509157 RESEARCH SUBCONTRACTS 2376972 2376972 168497 154342 14155 14217520 11066517 3151003 0 661334 8497842 13369794 265598 1157584 1078998 0 0 0 0 0 0 0 0 0 0 446287 651556 28890041 23129551 1998461 5760490 30211527 27411078 21493119 20152372 0 0 0 0 0 0 69338106 63817934 1418096 1766060 0 0 4179104 2576084 0 0 0 0 0 0 0 0 0 0 0 0 5597200 4342144 X 52202734 47847363 6538172 6628427 5000000 5000000 63740906 59475790 69338106 63817934 -3022508 -1242608 X false true X true true true X 13542106 11962028 10462429 10656034 8972211 55594808 0 0 0 0 0 0 0 0 0 0 13542106 11962028 10462429 10656034 8972211 55594808 11457232 44137576 2114186 1641406 1436270 5179805 2272845 12644512 0 0 0 5579 6 5585 0 0 0 0 0 68244905 803263 0.64675 0.63497 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8167358 151266 0 8318624 22246408 392663 14471713 8167358 20909389 2074290 737271 22246408 22339149 -681607 748153 20909389 22880697 180815 722363 22339149 0.60110 0.39890 false false 19087169 19087169 0 1995161 1995161 0 7807711 2047221 5760490 5760490 FUNDS OF FUNDS 8138416 F LIMITED PARTNERSHIPS 12013956 F 20152372 0 0 X 9791459 -1242608 -1242608 11034067 160945 160945 11195012 14056575 14056575 160945 160945 14217520 FORM 990, SCHEDULE D, PART V, QUESTION 4 USE OF FUND ENDOWMENTS: THE CENTER'S ENDOWMENT CONSISTS OF BOTH A DONOR-RESTRICTED ENDOWMENT FUND TO BE USED FOR AIDS RESEARCH AND A FUND DESIGNATED BY THE BOARD OF DIRECTORS TO FUNCTION AS ENDOWMENT. FORM 990, SCHEDULE D, PART X, QUESTION 2 The Center is subject to the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, "Income Taxes", relating to accounting and reporting for uncertainty in income taxes. Because of the Center's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Center's financial statements. Central America and the Caribbean Investments 3710131 3710131 3710131 true false false false true false Part I, Line 3, Column (f) Amount included in Schedule F is reported on the accrual basis of accounting. Part IV Foreign Investments The Center maintains investments in several foreign funds. The Center filed the appropriate 926 Form related to a transfer. However, the threshold for filing a FORM 8865 was not met and, accordingly, the Center did not file form 8865. X X X X X false true false false false false false true false DR DAVID D HO CHIEF EXECUTIVE OFFICER 676129 0 0 0 145155 0 80500 0 23773 0 925557 0 108969 0 KEVIN O'ROURKE CHIEF FINANCIAL OFFICER 256143 0 45000 0 0 0 41250 0 39855 0 382248 0 0 0 STEPHANIE SOZOMENU CHIEF OPERATING OFFICER 270202 0 55000 0 0 0 41250 0 23773 0 390225 0 0 0 MORIYA TSUJI SCIENTIST 174024 0 0 0 0 0 27000 0 23773 0 224797 0 0 0 YAOXING HUANG SCIENTIST 213894 0 0 0 0 0 32084 0 23773 0 269751 0 0 0 MARTIN MARKOWITZ INVESTIGATOR SCIENTIST 247540 0 0 0 0 0 37179 0 23773 0 308492 0 0 0 VINCENT SAHI CORE FACILITIES MANAGER 137458 0 0 0 0 0 21420 0 39855 0 198733 0 0 0 Teresa Evering SCIENTIST 135565 0 0 0 0 0 20986 0 13984 0 170535 0 0 0 XUELING WU SCIENTIST 139148 0 0 0 0 0 21465 0 39855 0 200468 0 0 0 MASAHIRO YAMASHITA SCIENTIST 121326 0 0 0 0 0 18333 0 13984 0 153643 0 0 0 SCHEDULE J, PART I, QUESTION 3 COMPENSATION PRACTICES: The executive compensation subcommittee's purpose is to review the CEO's employment agreement to ensure that the CEO's compensation package represents reasonable remuneration for the services performed and compliance with all applicable Federal, State, and Local laws. The subcommittee engaged an independent compensation consultant and completed a compensation study and report. The information provided by the compensation consultant is used by the compensation subcommittee to ensure that the terms of compensation recommended by this committee, including any non-monetary compensation, are considered reasonable. The recommendations are then brought to the full Board for approval. The compensation of other officers and key personnel are reviewed by the CEO for reasonableness. Promotions to these levels are recommended by the CEO and brought to the full Board for approval. part i, line 4b, During 2018, the Center contributed $18,500 and $19,400 into a 457(b) and 457(f) plan, respectively, for the CEO. Schedule J, Part I, Question 7 During 2018, CEO received $36,186 of retro payment related to the employment agreement and $108,969 of 457f pension distribution. FORM 990, PART VI, QUESTION 11 Governing body review of form 990: The Center's governing board receives a copy of the Form 990 prior to electronic Filing with the internal revenue service. The Center's Audit Committee is responsible for reviewing and approving the 990 for submission. FORM 990, PART VI, QUESTION 12C Monitoring and enforcement of compliance with conflicts of interest: Officers and directors are required, on an annual basis, to review, disclose potential conflicts, and sign the center's conflict of interests policy. FORM 990, PART VI, QUESTION 15 COMPENSATION PRACTICES: The executive compensation subcommittee's purpose is to review the ceo's employment agreement to ensure that the CEO's compensation package represents reasonable remuneration for the services performed and compliance with all applicable Federal, State, and Local laws. The subcommittee engaged an independent compensation consultant and completed a compensation study and report. The information provided by the compensation consultant is used by the compensation subcommittee to ensure that the terms of compensation recommended by this committee, including any non-monetary compensation, are considered reasonable. The recommendations are then brought to the full Board for approval. The compensation of other officers and key personnel are reviewed by the CEO for reasonableness. Promotions to these levels are recommended by the CEO and brought to the full Board for approval. FORM 990, PART VI, QUESTION 17 STATES: AL,AK,AZ,AR,CA,CO,CT,DE,DC,FL,GA,HI,ID,IN,IA,KS,KY,LA,ME,MD,MA,MI,MN,MS,MO ,MT,NE,NV,NH,NJ,NC,ND,OH,OK,OR,PA,RI,SC,SD,TN,TX,UT,VT,VA,WA,WV,WI,WY FORM 990, PART VI, QUESTION 19 GOVERNING DOCUMENTS AND ORGANIZATIONAL POLICIES: THE CENTER MAKES AVAILABLE THE MISSION STATEMENT AND THE ANNUAL FINANCIAL REPORT ON ITS WEBSITE. THE BY-LAWS, IRS FORM 990, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. Form 990, Part III, line 1 The Aaron Diamond AIDS Research Center for the City of New York, Inc. (the "Center"), incorporated in New York in 1988, is a research institute which houses a specialized viral containment laboratory where the HIV virus can be grown and biomedical research is undertaken. In fiscal year 2018, the Center's Board of Directors entered into negotiations with Columbia University ("Columbia") in which the Center would transfer substantially all of its assets to Columbia and Columbia would assume certain of the liabilities of the Center in connection with an integration of the Center's operations into Columbia. Upon closing of the transaction, the Center's activities and operations would relocate to Columbia as the Aaron Diamond AIDS Research Center within the Columbia University College of Physicians and Surgeons, for the purpose, amongst other things, combining the strengths of the institutions to enhance research and teaching in the area of HIV/AIDS, immunology and retro viruses. The Board approved the transaction at the Board meeting on February 9, 2018. The transfer is expected to be completed by December 31, 2019, when all major operations of the Center will cease. The Center, as a stand-alone entity, will continue to exist and conduct significantly reduced operations post-completion of the asset transfer for the foreseeable future.